
John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

Your AI-Trained Oncology Knowledge Connection!


John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.

John Michael "JM" Bryant, MD, discusses the combination of nivolumab with standard of care in the management of patients with prostate cancer, detailing the results of the interim analysis of the phase 2 trial.